Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 vs Semaglutide in Early-Stage Chinese T2DM Patients With Obesity (BRIGHT-1)
NCT07743983Phase 3Recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BGM0504 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction >= 10% from Baseline at 52 weeks. Started Sep 2026; status: recruiting.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07743983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743983.